H2SITE
17.11.2022 09:01:40 CET | Business Wire | Press release
Hydrogen takes a new step as a for the energy transition thanks to H2SITE, which has launched the world's first membrane manufacturing plant to obtain hydrogen from ammonia or methanol, and separate hydrogen from low concentration gas blends. The new facility will industrialize the production of membranes, the technological heart of H2SITE, used in the construction of hydrogen production reactors and separators. Similar membranes made of palladium alloys had been so far very costly, fragile, and difficult to manufacture and scale. H2SITE has managed to overcome these obstacles.
Located in Loiu (Biscay Region, Spain), the new H2SITE plant has a production capacity of tens of thousands of membranes per year. For its construction, H2SITE has invested more than 3 million euros, which it plans to double in the coming years to increase production capacity.
“Once the first production line has been validated, our objective is to significantly increase the capacity of the plant, vertically integrate the manufacturing process of the membrane and build new plants to tackle new markets,” according to Andrés Galnares, CEO of H2SITE. "Our objective is to significantly increase the number of membranes produced each year for the next 3 years, which entails continuing to invest in production assets similar to those we have already installed and increasing their level of automation to further reduce our costs.”
In 2022, H2SITE has booked orders of more than 5 million euros. Galnares assures that the goal is to double that figure over the next year, reaching a workforce of more than 50 professionals.
Asier Rufino, CEO of TECNALIA Ventures and President of H2SITE, states that "at TECNALIA we have been working for 20 years on the development and scaling up of hydrogen technologies its entire value chain: production, distribution, transport, storage and end uses. Together with the Technical University of Eindhoven (TU/e), the technology H2SITE leverages on was created. Today, H2SITE has scaled the process, has industrialized it, and is managing to reduce its cost to be able to develop new use cases”.
“This plant reflects the success of more than 10 years of collaboration initiated by TECNALIA and TU/e and supported by the Public Administration. H2SITE brings it to a new level with the industrialization of a disruptive process thanks to the help of investors who believe that technology is a critical enabler for the energy transition, such as ENGIE New Ventures, Breakthrough Energy Ventures, EQUINOR Ventures and institutional investors from the Basque Country Capital Riesgo País Vasco and Seed Capital Bizkaia. Along with the team that we have created, we cannot wish for better partners at this time," says Galnares.
The membrane separators and reactors will help provide hydrogen with high purity and limited cost, with focus on hard to abate industry sectors and heavy land and maritime mobility.
H2SITE is currently hiring in Europe. To learn more, follow H2SITE on LinkedIn.
About H2SITE
H2SITE was created in 2019 and has an exclusive technology of reactors separators for the conversion of different raw materials into hydrogen, among which are ammonia, methanol or synthetic gas, in addition to the separation of hydrogen from gaseous mixtures in low concentration.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005287/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom